Italia - italiensk - Ministero della Salute

landanger s.a. - divaricatori e retrattori per chirurgia generale - altri

Italia - italiensk - Ministero della Salute

landanger s.a. - divaricatori e retrattori per chirurgia generale - altri

Italia - italiensk - Ministero della Salute

landanger s.a. - divaricatori e retrattori per chirurgia generale - altri

Italia - italiensk - Ministero della Salute

internacional farmace�tica sa de cv - elettrocateteri permanenti - altri

Den europeiske union - italiensk - EMA (European Medicines Agency)

taw pharma (ireland) limited - clopidogrel cloridrato - peripheral vascular diseases; stroke; myocardial infarction; acute coronary syndrome - agenti antitrombotici - , , , , secondary prevention of atherothrombotic events, , clopidogrel is indicated in: , - adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. , - adult patients suffering from acute coronary syndrome:,    - non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). ,     - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy. , , in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is), clopidogrel in combination with asa is indicated in:, - adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event.  , , prevention of atherothrombotic and thromboembolic events in atrial fibrillation, in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. , , for further information please refer to section 5. , , ,.

Den europeiske union - italiensk - EMA (European Medicines Agency)

acino pharma gmbh - clopidogrel - peripheral vascular diseases; stroke; myocardial infarction - agenti antitrombotici - clopidogrel è indicato negli adulti per la prevenzione di eventi aterotrombotici in: * pazienti affetti da infarto miocardico (da pochi giorni fino a meno di 35), ischemico (da 7 giorni fino a meno di 6 mesi) o stabilito periferico malattia arteriosa. per ulteriori informazioni, si prega di fare riferimento alla sezione 5.

Den europeiske union - italiensk - EMA (European Medicines Agency)

tad pharma gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - agenti antitrombotici - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.

Den europeiske union - italiensk - EMA (European Medicines Agency)

sanofi winthrop industrie - clopidogrel idrogeno solfato - stroke; peripheral vascular diseases; atrial fibrillation; myocardial infarction; acute coronary syndrome - agenti antitrombotici - secondary prevention of atherothrombotic eventsclopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-st-segment-elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa);st-segment-elevation acute myocardial infarction, in combination with asa in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. in patients with moderate to high-risk transient ischemic attack (tia) or minor ischemic stroke (is)clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2  score ≥4) or minor is (nihss  ≤3) within 24 hours of either the tia or is event. prevenzione di atherothrombotic e di eventi tromboembolici in fibrillazione fibrillationin pazienti adulti con fibrillazione atriale che hanno almeno un fattore di rischio per eventi vascolari, non sono adatti per il trattamento con vitamina-k antagonisti e che hanno un basso rischio di sanguinamento, il clopidogrel è indicato, in associazione con asa per la prevenzione di atherothrombotic ed eventi tromboembolici, tra cui ictus.

Den europeiske union - italiensk - EMA (European Medicines Agency)

actavis group ptc ehf - reteplase - infarto miocardico - agenti antitrombotici - rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent st elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (ami) symptoms.

Italia - italiensk - Ministero della Salute

respicardia, inc. (formerly cardiac concepts, inc.) - neurostimolatori del nervo frenico